The Covid-19 vaccine developed by AstraZeneca and the University of Oxford generated $ 275 million in sales out of around 68 million doses delivered in the first three months of this year, AstraZeneca reported on Friday.
AstraZeneca released the figure, most of which came from sales in Europe, when releasing its first quarter financial results. It offers the clearest view to date of the amount of money contributed by one of the main Covid vaccines.
AstraZeneca, which has pledged not to profit from its vaccine during the pandemic, sold the vaccine to governments for several dollars per dose, cheaper than other major vaccines. The vaccine has obtained approval in at least 78 countries since December, but it is not approved for use in the United States.
The Covid vaccine represented just under 4 percent of AstraZeneca’s revenue for the quarter; it was far from being the company’s biggest revenue generator. By comparison, the company’s best-selling product, the cancer drug Tagrisso, generated more than $ 1.1 billion in sales in the quarter.
AstraZeneca said it plans to seek emergency clearance for its vaccine for use in the United States, even as it has become clear that doses are not needed. The Biden administration said this week that it would make up to 60 million doses of its supply of AstraZeneca injections available to the rest of the world, pending a review of their quality.
If the company gets clearance from the U.S. Food and Drug Administration, it could help build confidence in a vaccine whose reputation has been affected by concerns about a rare but serious side effect involving blood clotting. The FDA review process is considered the gold standard in the world.
Johnson & Johnson, whose vaccine was cleared for emergency use at the end of February, reported last week that its vaccine generated $ 100 million in sales in the United States in the first three months of the year. The federal government pays the company $ 10 a dose. Like AstraZeneca, Johnson & Johnson have pledged to sell their vaccine “at cost” – meaning it won’t profit from sales – during the pandemic.
Pfizer and Moderna’s vaccines cost more, and neither company has said it will forgo profits. Pfizer has said it expects its vaccine to bring in around $ 15 billion in revenue this year; Moderna said he expected revenue of $ 18.4 billion.
Both companies are expected to release their first quarter results next week.